H ypertension affects ≈80 million adults in the United States, and its prevalence is increasing as the population ages.
H ypertension affects ≈80 million adults in the United States, and its prevalence is increasing as the population ages. 1 Elevated systolic blood pressure (BP) is associated with progression of carotid arterial stiffening. 2, 3 Treating hypertension reduces cardiovascular disease (CVD) and stroke events, an observation that may be mediated, in part, by slowing progressive arterial stiffening. 1, [4] [5] [6] [7] [8] Previous studies have associated hypertension with reduced carotid distensibility and elasticity, and more recent data suggest that increased arterial stiffness may cause hypertension [9] [10] [11] ; however, it is not known whether certain classes of antihypertensive medications have differing effects on the long-term progression of arterial stiffness. Clinical trials have had mixed results on the effects of classes of antihypertensive medications; however, their follow-up periods were short, most were head-to-head trials of antihypertensive monotherapies, and minorities were underrepresented.
Furthermore, none have compared the wide array of commonly prescribed medications. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] To our knowledge, no studies have evaluated the association of classes of antihypertensive medications on local arterial stiffness parameters in a single, ethnically diverse, large population with extended follow-up. This study sought to determine the longitudinal associations between use of specific classes of antihypertensive medications and changes in carotid artery distensibility and elasticity over a 10-year period in a large, ethnically diverse cohort without clinically evident CVD at baseline.
Methods

Study Participants and Design
The MESA (Multi-Ethnic Study of Atherosclerosis) is a populationbased cohort of 6814 men and women aged 45 to 84 years, free of Abstract-Associations with antihypertensive medication classes and progression of arterial stiffness have not been studied in a prospective multiethnic cohort. All participants had hypertension at baseline, defined as blood pressure ≥140/90 mm Hg or use of antihypertensive medications. Medication use and blood pressure were assessed at 5 time points. Young's elastic modulus and distensibility coefficient of the right common carotid artery were obtained by ultrasound at baseline and after a mean (SD) follow-up period of 9.4 (0.5) years. Associations with changes in Young's elastic modulus and distensibility coefficient, baseline antihypertensive medication use, number of visits each medication class was reported, and blood pressure control (<140/90 mm Hg) were assessed using multiple linear regression models. At baseline, mean age of participants (n=1206) 
P=0.001).
Blood pressure control, rather than use of any particular antihypertensive medication class, was associated most strongly with slowing arterial stiffness progression. Over nearly a decade of follow-up, no consistent associations between any specific antihypertensive medication class and progressive carotid arterial stiffening were identified. (Hypertension.
known CVD at baseline, recruited from 6 US communities. The study objectives and design have been published previously. 22 All participants gave informed consent for participation, which was approved by the institutional review boards of the ultrasound reading center and all MESA field centers. This report is of the subset of MESA participants with valid carotid distensibility measurements at examination 1 (baseline) and examination 5 (n=2650) and who also had hypertension at baseline (45% of those with all distensibility measurements; n=1206). Carotid artery distensibility coefficient (DC) and Young's elastic modulus (YEM) were calculated using standard accepted formulae 6, 23 and have been reported previously. 3, 24 Demographic, medical history, and laboratory data for this study were obtained from the first ( 
Brachial Artery BP Measurements and Carotid Artery B-Mode Ultrasound
At each examination, repeated measures of brachial artery BPs were obtained using a standardized protocol with an automated upper arm sphygmomanometer (DINAMAP, GE Medical Systems, Milwaukee, WI). At examinations 1 and 5, participants rested in the supine position for 10 minutes, and BP measurements were obtained immediately before the ultrasound image acquisition during examinations 1 and 5. BP measurements also were made at examinations 2, 3, and 4 using similar methods after 5 minutes of rest in the seated position. At examinations 1 and 5, B-mode ultrasound video loop recordings of a longitudinal section of the distal right common carotid artery were recorded on videotape using a Logiq 700 ultrasound system (General Electric Medical Systems, transducer frequency 13 MHz).
Trained, certified sonographers used preselected reference images from examination 1 to match the scanning location and imaging conditions of the initial study, including segment of the distal right carotid artery, angle of approach, internal landmarks, degree of jugular venous distension, and ultrasound system settings, including display depth. 3 Measurements of examinations 1 and 5 carotid ultrasound images were performed simultaneously. Digital images were matched side by side on a video monitor and measured contemporaneously. Readers were blinded to all clinical information, including age, sex, race, use of antihypertensive medications, and BP readings.
Because the ultrasound loops were not ECG-gated, systolic and diastolic carotid artery diameters were determined visually by highly trained technicians (described below) as the largest and smallest diameters during the cardiac cycle. They were measured manually using a digital edge tracing tool and performed in triplicate from 2 to 3 consecutive cardiac cycles using Access Point Web version 3.0 (Freeland Systems, LLC, Westminster, CO).
Regarding the comparability of the examination 1 and examination 5 images, we determined that the size of a digitized pixel using the Medical Digital Recording device was 0.056 mm. A systematic bias of <1/2 digital pixel (0.028 mm) was statistically rejected using the two, 1-sided t test, 25 thus demonstrating equivalence of both measurements using digitized videotape and digitized video stream. We also performed paired, blinded measurements of the diameter of a simulated blood vessel in an ultrasound phantom. There was excellent agreement with mean (SD) diameters of 3.47 (0.02) mm for digitized videotape and 3.47 (0.01) mm for digitized video stream (t test P=0.660). On the basis of these findings and the visual appearance of essentially superimposable images from digitized videotape and video stream, even if a small bias existed, it would not affect the relationships between the covariates (ie, it only would affect the absolute values of the measurements).
To assess measurement reproducibility, a blinded reader measured 25 representative images, twice. Reproducibility was excellent for all measurements with minimal bias and strong Pearson correlation coefficients for all component measurements: internal end-diastolic diameter (r=0.998), peak systolic internal diameter (r=0.998), end-diastolic external diameter (r=0.997), change in diameter (r=0.925), and wall thickness (r=0.989; all P values<0.001) and an intraclass correlation coefficient (96% confidence interval) of 1.0 (0.99-1.0) for end-diastolic internal diameter, 0.98 (0.96-0.99) for wall thickness, and 0.85 (0.72-0.92) for derived delta diameter and no significant bias.
Approximately 90% of readings were performed by 2 readers. Inter-reader Pearson correlations were 0.99 for all 3 diameter measurements, 0.94 for derived delta diameter and 0.96 for wall thickness and intraclass correlation coefficient (95% confidence interval) of 0.99 (0.99-1.0) for end-diastolic internal diameter, 0.92 (0.85-0.96) for wall thickness, and 0.87 (0.76-0.93) for derived delta diameter with no significant bias. Of note, each reader read both sets of distensibility studies for each subject within the same sitting, so there is no bias by reader within subjects, which is the basis of all of our analyses.
Statistical Analyses
Multiple linear regression models were used to model changes in DC and in YEM as functions of 6 commonly prescribed classes of antihypertensive medications (diuretics, calcium channel blockers [CCBs], angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, β-blockers, and vasodilators) at baseline. Models were adjusted for baseline age, sex, race/ethnicity, CVD risk factors (body mass index, diabetes mellitus status [impaired fasting glucose, treated diabetes mellitus, untreated diabetes mellitus], systolic BP, lipid levels, physical activity, alcohol use, and smoking status), and estimated glomerular filtration rate. All models were performed with adjustment for baseline carotid artery stiffness measures. Analyses were repeated without baseline carotid arterial stiffness measures, and no consistent differences in the associations with medication classes were found (data not shown). Subsequent regression models evaluated associations between changes in DC and in YEM with the number of visits (1-5) each individual medication class was prescribed, adjusting for baseline CVD risk factors. Each drug class was estimated in a separate fully adjusted regression model that included adjustment for baseline use of the antihypertensive medication class and baseline stiffness measures. For each drug class, the reference group was hypertensive participants who were untreated at all visits. Similar models were repeated using treatment status (treated versus untreated at all visits) and BP control (treated and controlled versus treated but uncontrolled at all visits), as exposure variables in separate models. Because individuals could be taking antihypertensive medications from >1 drug class, sensitivity analyses were performed limited to hypertensive participants who were untreated at baseline and compared those who took only a single antihypertensive medication at visits 2, 3, and 4 with those who remained untreated at visits 2, 3, and 4. Analyses were performed using Stata 13 (StataCorp 2013, StataCorp LP, TX).
Results
Participant Characteristics
Baseline participant characteristics are shown in Table 1 . All participants had hypertension (n=1206); they were a mean (SD) of 63.2 (9.0) years old and 54.8% were female. The participants were 34.2% white, 34.8% African American, 19.2% Hispanic, and 11.8% Chinese. At each of the 5 visits, participants were taking a wide range of antihypertensive medications representative of those commonly used in the United States: diuretics (n=298), CCBs (n=291), angiotensin-converting enzyme inhibitors (n=277), angiotensin receptor blockers (n=85), β-blockers (n=231), and other vasodilators (n=103). There were 273 (22.6%) hypertensive participants that were untreated at baseline. Over the ≈10 years of follow-up, average systolic BP decreased from 136. 4 (20.6) During the period between examination 1 and examination 5, there were few CVD events: MI (3.3%, n=39), incident CHF (2.8%, n=34), and incident stroke (3.1%, n=37). Table 2 ). Over the study period, there appeared to be somewhat less progression of arterial stiffness with long-term use of β-blockers (Table 3) ; however, the strength of the relationship was not strong (increased DC: β=0.49×10 −4 mm Hg −1 , P trend =0.016; decreased YEM: β=−58.6 mm Hg, P trend =0.03). Similarly, a weak signal suggests that long-term use of other vasodilators also had less worsening of DC (β=0.67×10 −4 mm Hg −1 , P trend =0.049) but not YEM (β=−4.5 mm Hg, P trend =0.9), but the number of participants on long-term other vasodilators was small (n=33). In sensitivity analyses limited to hypertensive participants who were untreated at baseline and were only on a single antihypertensive class treatment with a single drug class at all visits (2, 3, and 4) and some visits (2, 3, or 4) had no difference in progression of DC or YEM (all P>0.2) with any class of antihypertensive medication. When the models were limited to a single antihypertensive medication class, there were no consistent differences by class, although these were limited by small sample sizes.
BP Control With Any Class of Antihypertensive Medication
On average, carotid artery DC decreased and YEM increased, indicating progressive arterial stiffening, over the study period in all groups (Figures 1 and 2 All estimates were adjusted for age, sex, race, and traditional cardiovascular disease risk factors (baseline systolic blood pressure, diabetes mellitus status, smoking status, total cholesterol, high-density lipoprotein cholesterol, physical activity, estimated glomerular filtration rate, body mass index, baseline alcohol use, baseline use of antihypertensive medications, and respective baseline stiffness measures). CI indicates confidence interval.
*Compared with participants not taking each specific medication class at baseline. *Each drug class was estimated in a separate regression model and adjusted for age, sex, race, and traditional cardiovascular disease risk factors (baseline systolic blood pressure, diabetes mellitus status, smoking status, total cholesterol, high-density lipoprotein cholesterol, physical activity, estimated glomerular filtration rate, body mass index, baseline alcohol use, baseline use of antihypertensive medications, and respective baseline stiffness measures). For each drug class, the reference group was hypertensive participants who were untreated at all visits.
†Treated at all examinations (n=682), compared with those who were untreated at all visits (n=56). ‡Treated and controlled at all examinations (n=243), compared with treated and uncontrolled hypertension (BP>140/90 mm Hg) at all visits (n=82).
mm Hg) at all visits ( Figures 1A and 2A) . When included in the multivariable analyses, treatment with a specific antihypertensive medication class was not associated with improvements in DC or YEM (Table 3) . Conversely, treatment with any antihypertensive medication and controlled BP (<140/90 mm Hg) at all visits was associated with less progression of arterial stiffness (change in DC: β=7.34×10 −4 mm Hg −1 , P=0.001; change in YEM: β=−790.1 mm Hg, P=0.01) compared with those with uncontrolled BP at all visits ( Figures  1B and 2B) . In sensitivity analyses limited to hypertensive participants who were untreated at baseline, those with controlled BP (<140/90 mm Hg) at all visits (2, 3, and 4) had less decrease in DC (β=5.37×10 −4 mm Hg −1 , P=0.001) and less increase in YEM (β=−610.7 mm Hg, P=0.011) compared with participants with uncontrolled BPs at visits 2, 3, and 4 (Table S2) .
Discussion
This analysis showed that among hypertensive participants, weak, inconsistent effects of individual antihypertensive classes of medications on progressive arterial stiffening were seen; however, BP control, regardless of medication(s) used, was associated with a slower progression of arterial stiffness. Participants with higher baseline BP were more likely to be started on antihypertensive therapy during the study period, which accounts for the overall reduction in BP during the study period; initiating antihypertensive therapy has been previously shown to slow progression of stiffness measures in the MESA. 3 Treatment with antihypertensive therapy also has been shown to be associated with less progression of carotid intima-media thickness, 26 which leads to decreased progression of overall wall thickness (h), a component of the YEM calculation.
In this analysis, African American ethnicity was associated strongly with greater progression of carotid arterial stiffness (DC and YEM) and weakly with DC in Hispanic participants compared with white participants, but no statistically significant associations were noted with arterial stiffness measures in hypertensive Chinese participants. Previous analyses showed that Chinese ethnicity was associated with slower progression of DC but not YEM. These findings are likely, in part, related to the differences in the prevalence of hypertension among the different ethnic groups. Also, there are clear socioeconomic differences between ethnic groups within MESA, which have been shown to impact healthcare access and likely have an impact on who receives optimal treatment of hypertension over time. 27 Previous analyses in the MESA showed that advanced age and systolic BP were associated with increased carotid arterial stiffness. 3 Baseline use of antihypertensive medication and stopping antihypertensive medication also were associated with faster progression of YEM and starting on antihypertensive medication was associated with slower progression of DC. 3 Clinical trials have had mixed results on the effects of classes of antihypertensive medications on arterial stiffness measures. 12 In clinical trials, improvements in arterial stiffness measures have been described with CCBs, 13, 14 and vasodilators 28, 29 but mixed results for treatment with angiotensin-converting enzyme inhibitors, 15, 16 angiotensin receptor blockers, [16] [17] [18] and β-blockers 15, 18, 19 have been reported. Diuretics have not had a robust effect on arterial stiffness measures. 20, 21 However, many of these trials were limited by short follow-up periods, small sample sizes, exclusive use of antihypertensive monotherapies, and were under-representative of racial/ethnic minorities.
A recent large meta-analysis showed that carotid arterial stiffness is associated with incident stroke independent of CVD factors and aortic stiffness 8 ; thus, slowing progression carotid stiffness likely has important prognostic applications. This observation gives the clinician justification to apply other guideline-based treatment strategies (eg, angiotensin-converting enzyme/angiotensin receptor blocker for diabetes mellitus or heart failure, β-blockers for coronary artery disease) or altering therapy because of intolerable side effects without concern for the specific effects on arterial stiffness measures.
Limitations
The MESA is an observational study, and the limitations of any observational study apply, including residual confounding and selection bias, a bias because of survival to the fifth examination visit. Although considerable efforts were taken to standardize and match the carotid images between examination 1 and examination 5, there is a possibility that stiffness parameters could vary based on the exact measurement location within the vessel tree. However, our reproducibility was excellent, as described above. The association between CCB use and greater increases in carotid artery stiffness parameters may represent confounding by indication because of preferential use of these medications in older patients or African Americans. 30 The reported associations do not confirm causation; longitudinal follow-up from clinical trials of antihypertensive therapy is needed to confirm the effects of therapy we observed. Brachial artery BP measurements and antihypertensive medication use were obtained at 5 visits over the ≈10-year follow-up period, so that they may not accurately represent the average BP during that time period. Also, the duration of exposure to hypertension and antihypertensive medications before the baseline visit are not known. The intervals between each study visit were similar but not precisely uniform, and adherence to medication was not confirmed. The diuretic class includes loop diuretics, thiazide diuretics, and potassium-sparing diuretics, which theoretically could have differing effects on arterial stiffness; however, the number of participants on potassium-sparing diuretics was small (≈2%). BP constantly fluctuates in response to normal physiological stimuli, unlike age, which progresses at the same linear rate for all participants. Similarly, many subjects were on a combination of antihypertensive therapies. These participants pose additional challenges in attributing associations to a particular medication and could bias results toward the null hypothesis. Further analyses evaluating participants who were untreated at baseline but were treated at examinations 2, 3, and 4 with a single agent similarly revealed that BP control, rather than specific class of antihypertensive medication, had an impact on progression of stiffness. Brachial artery BP measurements were surrogates for carotid arterial pressures in the DC and YEM calculations. Although a standard practice in epidemiological studies, brachial artery BP measurements can overestimate central pressures, although this difference is smaller in older participants and also would amplify null bias. 23, 31 Finally, the relatively small sample sizes when broken down by medication class may not have adequate power to detect significant results.
Perspectives
Our key finding is that no specific antihypertensive medication class was associated robustly with delayed progression of arterial stiffness; however, there is a consistent relationship between BP control and reducing progression of stiffness. From a clinical standpoint, these findings are important and may suggest that the specific class of antihypertensive medication should not be the primary focus in trying to prevent further progression of arterial stiffness; rather using any medication class or classes that effectively reduce the BP to goal should delay progressive arterial stiffening and its CVD consequences, although large randomized trials are needed for confirmation.
